ISA 201Alternative Names: Hespecta; HPV E-Six Peptide Conjugated To AMPLIVANT®; HPV16 E6 Peptide Conjugated To AMPLIVANT®; HPV16 peptides AMPLIVANT® vaccine; ISA201; SLP AMPLIVANT® head and neck cancer vaccine
Latest Information Update: 04 Mar 2015
At a glance
- Originator ISA Pharmaceuticals
- Class Cancer vaccines; Peptide vaccines; Peptides
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Head and neck cancer; Human papillomavirus infections